Form D · Pharmaceuticals
Paulex Bio Inc.
La Jolla, CA · CIK 0002071082
Offering snapshot reported Dec 18, 2025 · SEC filing
- Reported sold
- $18.5M Offering amount: $22.5M
- Investors reported
- 163 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 21, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 18, 2025 | Initial | $18,516,040 | No comparison | 163 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.58M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-567385
Sales commission estimate based on assumption of maximum offering amount sold.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| MDB Capital | 000042677 |
Source: Form D, filed Dec 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mohammad Hayat | Director |
| Francisco Leon | Director |
| Sanjuan Miguel | Director, Executive |
| Edgardo Rayo | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6083 Oakgate Row
La Jolla, CA, 92037
La Jolla, CA, 92037